The American Academy of Allergy Asthma and Immunology
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$41,482,525
Investments
70%
Cash & Equivalents
27%
Receivables (Non-Related)
2%
Prepaid Expenses
1%
Other Assets
<1%
Property, Plant, & Equipment (net)
<1%
Related-Party Receivables
0%
Inventories
0%
Liabilities in 2024 (Year End)
$6,864,485
Deferred Revenue
85%
Grants Payable
10%
Payables & Accruals
5%
Other Liabilities
<1%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$9,718,279
$11,151,824
+15%
Receivables (Non-Related)
$1,075,575
$647,956
-40%
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$379,081
$591,634
+56%
Investments
$26,510,273
$28,858,008
+9%
Property, Plant, & Equipment (net)
-
$31,964
-
Other Assets
$156,425
$201,139
+29%
Total Assets
$37,839,633
$41,482,525
+10%
Liabilities
2023
2024
Change
Payables & Accruals
$362,826
$351,491
-3%
Grants Payable
$295,000
$658,935
+123%
Deferred Revenue
$4,470,740
$5,853,080
+31%
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
$17,782
$979
-94%
Total Liabilities
$5,146,348
$6,864,485
+33%
Net assets
2023
2024
Change
Restricted Net Assets
$392,703
$241,917
-38%
Unrestricted Net Assets
$32,300,582
$34,376,123
+6%
Net assets
2023
2024
Change
Net assets
+$32,693,285
+$34,618,040
+6%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)